register

News & Trends - MedTech & Diagnostics

Precision cancer care at tenfold the speed of conventional imaging technologies

Health Industry Hub | October 6, 2023 |

MedTech & Diagnostics News: Icon Cancer Centre Holmesglen in Victoria has embraced Varian’s HyperSight technology, revolutionising imaging capabilities by capturing high-resolution tumour images in a mere six seconds, a speed tenfold greater than conventional systems. This exceptional medical technology advancement is poised to elevate cancer treatment guidance, ensuring optimal care for patients.

Pioneering as one of the premier centres in the Southern Hemisphere to integrate Varian’s HyperSight, Icon Cancer Centre is setting a new standard in cancer treatment. A “revolution in resolution”, according to Kevin O’Reilly, President of Radiation Oncology Solutions for Varian, HyperSight leverages cone-beam computed tomography (CBCT) to provide images with unparalleled contrast and superior quality.

Developed by Varian, a Siemens Healthineers company, HyperSight received TGA approval for use on Varian’s Ethos and Halcyon image-guided radiation therapy systems in February this year. Its ability to encompass a larger imaging area with remarkable precision and speed surpasses conventional technologies on radiation therapy systems, reducing patient discomfort and anxiety during treatments.

Recent comparative research evaluating Varian HyperSight against Varian Truebeam kV-CBCT (TB) and GE Siemens kV-FBCT CT scanner (GE) in standard pelvis, thorax, and breast protocols reaffirms HyperSight’s supriority. The study showcased several instances where HyperSight’s imaging exhibited superior quality, and in other cases where resolution was on par with TB or GE, HyperSight’s performance remained consistently equivalent.

Claire Smith, Director of Radiation Therapy at Icon Group, emphasised the technology’s profound impact, stating, “We can pinpoint and map tumours in the patient almost in real time.” She highlighted the significant benefits already witnessed in the early stages of implementation, emphasising the positive effects on clinical teams, patients, and operational workflows.

“We are still assessing the impact it is having on our clinical workflows, like preventing unnecessary trips to a CT scanner, and reducing the time a patient needs to be on the treatment bed. Having this capability on the machine in the treatment room is already proving positive with our radiation therapists,” said Ms Smith.

In contrast to traditional radiation therapy imaging systems, which can take up to 60 seconds and necessitate patients to hold their breath for a clear image, HyperSight is designed to significantly reduce motion-related image blurring. Particularly critical in lung, liver, and left breast cancer cases where tumours are prone to movement, HyperSight’s innovation ensures clear, precise imaging at the point of treatment.

HyperSight images provide crucial data detailing how radiation therapy treatment impacts both the tumor and surrounding anatomy. The improved quality of CBCT images enables precise calculations of changes within the tumor and nearby organs. Previously, such calculations were hindered by image quality limitations or necessitated additional CT scans on separate machines, potentially prolonging the patient’s stay in the hospital.

As HyperSight continues to demonstrate its potential, Ms Smith remains optimistic about its broader application across cancer centres in Australia and beyond, foreseeing its potential to streamline clinical workflows and minimize patient time on the treatment bed.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Manoj Saxena - Bayer

Breaking the mold: Bayer GM on the future of pharma workplaces – Reimagining Healthcare Senior Leadership Series

Health Industry Hub | July 18, 2024 |

In the latest episode of the Reimagining Healthcare senior leadership series, Manoj Saxena, General Manager Pharmaceuticals ANZ at Bayer voiced […]

More


News & Trends - Pharmaceuticals

Matt Zeller, Country President of Novartis ANZ

Novartis Country President talks essentials in shaping the future of health policy: Reimagining Healthcare senior leadership series

Health Industry Hub | July 18, 2024 |

In this episode of the Reimagining Healthcare senior leadership series, Matt Zeller, Country President of Novartis ANZ, explores how health […]

More


Medical

First guidelines to stamp out rising scientific integrity issues in medical journals

First guidelines to stamp out rising scientific integrity issues in medical journals

Health Industry Hub | July 18, 2024 |

The number of retractions issued for scientific research articles in 2023 exceeded 10,000 – smashing annual records. To date, publishers […]

More


News & Trends - Pharmaceuticals

Gilead secures MSAC nod for CAR-T therapy

Gilead secures MSAC nod for CAR-T therapy

Health Industry Hub | July 18, 2024 |

Pharma News: Gilead Sciences welcomes the Medical Services Advisory Committee (MSAC) recommendation for public funding of Yescarta (axicabtagene ciloleucel) as […]

More


This content is copyright protected. Please subscribe to gain access.